FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2922047567> ?p ?o ?g. }

• W2922047567 endingPage "95" @default.
• W2922047567 startingPage "85" @default.
• W2922047567 abstract "Background Histological parameters of primary tumour and nodal metastases are prognostic factors for survival of operable colorectal (CRC) patients, but not predictive for response rate of systemic therapy. KRAS mutations in codons 12 and 13 were first recognized as a predictive factor for resistance to anti-EGFR monoclonal antibodies. Not all patients with wild-type KRAS (wtKRAS) respond to anti-EGFR antibody treatment. Additional mechanisms of resistance may activate mutations of the other main EGFR effectors pathway, such as other mutations in RAS gene, mutations in P13K and PTEN expression. Patients and methods In the prospective study prognostic and predictive impact of histological parameters of primary tumour, KRAS and BRAF mutations on overall survival (OS) and objective response (OR) rate of metastatic CRC (mCRC) patients treated with 1st line systemic therapy were analysed. We additionally retrospectively analysed other mutations in RAS genes and their impact on survival and time to progression. Results From November 2010 to December 2012, we enrolled 154 patients in the study, 95 men and 59 women. Mutations in KRAS gene and V600E BRAF gene were found in 42% and in 3% of patients, respectively. Median OS of the patients with T1, T2 and T3 tumour was 65.4 months (95% CI, 55.7-75.6) while in patients with T4 tumour, lymphangiosis, vascular and perineural invasion it has not been reached yet. Median OS of the patients with G1, G2 and G3 of tumour differentiation was 65.6 (95% CI, 53.7-77.5) and 25.3 months (95% CI, 16.6-34.1), respectively. Median OS of the patients with stage N0, N1 and N2 was 65.6 (95% CI, 56.4-74.8) and 58.0 months (95% CI, 21.9-94.2), respectively. Median OS of wtKRAS and mutated KRAS patients was 56.5 (95% CI, 48.2-64.9) and 58 months (95% CI, 52.6-63.4), respectively. Median OS of mutated codon 12 and codon 13 patients was 57 (95% CI, 50.9-64.4) and 44 months (95% CI, 40.1-48.4), respectively. Median OS of wtBRAF and of mutated BRAF patients was 59.2 (95% CI, 52.5-65.9) and 27.6 months (95% CI, 12.6-42.5), respectively. wtKRAS significantly affected the response to the first systemic therapy (p = 0.028), while other parameters did not affected it, p= 0.07. In 14 patients (17%), additional mutations in NRAS gene, codon 61 and codon 146 were found. Median OS of wtNRAS, codon 61 and 146 patients was 67.1 months (50.3-67.6) while median OS of mutated NRAS patients has not been reached yet (p = 0.072). Median time to progression of wtNRAS, codon 61 and 146 patients was 11.7 months (10.4-14.5) while median time to progression of mutated NRAS patients was 7.9 months (6.1-11.0), (p = 0.025). Conclusions Mutated BRAF, N2 and G3 of primary tumour were poor prognostic factors for OS in mCRC patients. wtKRAS significantly affected the response to the first line systemic therapy. Histological parameters included in the analysis and mutated BRAF did not affect significantly the efficacy of 1st line systemic therapy in mCRC patients." @default.
• W2922047567 created "2019-03-22" @default.
• W2922047567 creator A5013032782 @default.
• W2922047567 creator A5022130181 @default.
• W2922047567 creator A5045771155 @default.
• W2922047567 creator A5067298588 @default.
• W2922047567 date "2019-03-01" @default.
• W2922047567 modified "2023-10-05" @default.
• W2922047567 title "Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients" @default.
• W2922047567 cites W1870988441 @default.
• W2922047567 cites W1940241680 @default.
• W2922047567 cites W1967628954 @default.
• W2922047567 cites W1974365898 @default.
• W2922047567 cites W2003157997 @default.
• W2922047567 cites W2006330201 @default.
• W2922047567 cites W2007420407 @default.
• W2922047567 cites W2019607817 @default.
• W2922047567 cites W2019718580 @default.
• W2922047567 cites W2028351764 @default.
• W2922047567 cites W2035384960 @default.
• W2922047567 cites W2036045525 @default.
• W2922047567 cites W2049282019 @default.
• W2922047567 cites W2064550547 @default.
• W2922047567 cites W2067296180 @default.
• W2922047567 cites W2069884383 @default.
• W2922047567 cites W2070625845 @default.
• W2922047567 cites W2082522255 @default.
• W2922047567 cites W2083704677 @default.
• W2922047567 cites W2086808621 @default.
• W2922047567 cites W2095692554 @default.
• W2922047567 cites W2103461959 @default.
• W2922047567 cites W2103856575 @default.
• W2922047567 cites W2113302375 @default.
• W2922047567 cites W2114545185 @default.
• W2922047567 cites W2116911901 @default.
• W2922047567 cites W2119347977 @default.
• W2922047567 cites W2121785313 @default.
• W2922047567 cites W2121869934 @default.
• W2922047567 cites W2122074158 @default.
• W2922047567 cites W2126948867 @default.
• W2922047567 cites W2134519717 @default.
• W2922047567 cites W2138926750 @default.
• W2922047567 cites W2141801755 @default.
• W2922047567 cites W2144026118 @default.
• W2922047567 cites W2152490158 @default.
• W2922047567 cites W2159064822 @default.
• W2922047567 cites W2161593277 @default.
• W2922047567 cites W2164311019 @default.
• W2922047567 cites W2170866713 @default.
• W2922047567 cites W2171722677 @default.
• W2922047567 cites W2319812787 @default.
• W2922047567 cites W2470575266 @default.
• W2922047567 cites W2563379937 @default.
• W2922047567 cites W4236891330 @default.
• W2922047567 cites W560543370 @default.
• W2922047567 doi "https://doi.org/10.2478/raon-2019-0013" @default.
• W2922047567 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6411021" @default.
• W2922047567 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30840593" @default.
• W2922047567 hasPublicationYear "2019" @default.
• W2922047567 type Work @default.
• W2922047567 sameAs 2922047567 @default.
• W2922047567 citedByCount "4" @default.
• W2922047567 countsByYear W29220475672019 @default.
• W2922047567 countsByYear W29220475672020 @default.
• W2922047567 countsByYear W29220475672021 @default.
• W2922047567 countsByYear W29220475672023 @default.
• W2922047567 crossrefType "journal-article" @default.
• W2922047567 hasAuthorship W2922047567A5013032782 @default.
• W2922047567 hasAuthorship W2922047567A5022130181 @default.
• W2922047567 hasAuthorship W2922047567A5045771155 @default.
• W2922047567 hasAuthorship W2922047567A5067298588 @default.
• W2922047567 hasBestOaLocation W29220475671 @default.
• W2922047567 hasConcept C121608353 @default.
• W2922047567 hasConcept C126322002 @default.
• W2922047567 hasConcept C143998085 @default.
• W2922047567 hasConcept C185592680 @default.
• W2922047567 hasConcept C190283241 @default.
• W2922047567 hasConcept C2777154038 @default.
• W2922047567 hasConcept C2777609662 @default.
• W2922047567 hasConcept C2778332735 @default.
• W2922047567 hasConcept C2780521871 @default.
• W2922047567 hasConcept C2781187634 @default.
• W2922047567 hasConcept C2781230642 @default.
• W2922047567 hasConcept C526805850 @default.
• W2922047567 hasConcept C55493867 @default.
• W2922047567 hasConcept C71924100 @default.
• W2922047567 hasConcept C86554907 @default.
• W2922047567 hasConceptScore W2922047567C121608353 @default.
• W2922047567 hasConceptScore W2922047567C126322002 @default.
• W2922047567 hasConceptScore W2922047567C143998085 @default.
• W2922047567 hasConceptScore W2922047567C185592680 @default.
• W2922047567 hasConceptScore W2922047567C190283241 @default.
• W2922047567 hasConceptScore W2922047567C2777154038 @default.
• W2922047567 hasConceptScore W2922047567C2777609662 @default.
• W2922047567 hasConceptScore W2922047567C2778332735 @default.
• W2922047567 hasConceptScore W2922047567C2780521871 @default.
• W2922047567 hasConceptScore W2922047567C2781187634 @default.
• W2922047567 hasConceptScore W2922047567C2781230642 @default.

• next